Compass Therapeutics, Inc. (Nasdaq:CMPX)
Health Care/Life Sciences • Biotechnology
CIK 1738021
Company
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.
Address
80 Guest Street
Suite 601
Boston, Massachusetts 02135
80 Guest Street
Suite 601
Boston, Massachusetts 02135
Employees
32
32
Stock Info
Close
$2.7700
$2.7700
Day Range
2.6800 - 2.9800
2.6800 - 2.9800
52 Week Range
0.7650 - 4.0800
0.7650 - 4.0800
Average volume
1.35M
1.35M
Short Interest
3.53M (02/14/25)
3.53M (02/14/25)
% of Float Shorted
4.38%
4.38%
Market Cap
$383.04M
$383.04M
Revenue
N/A
N/A
Net Income
-$42.49M
-$42.49M
2020 Sales Growth
N/A
N/A
Key Executives
Board Of Directors
Chairman Carl Lee Gordon |
Independent Director Phil J. Ferneau |
Independent Director Ellen V. Chiniara |
Independent Director Mary Ann Gray |
Independent Director James P. Boylan |
Independent Director Richard Scott Lindahl |
SEC filings
Date | Form | Event |
---|---|---|
10 Dec, 2024 | 8-K | |
10 Dec, 2024 | 4 | |
10 Dec, 2024 | 3 | |
10 Dec, 2024 | 3 | |
14 Nov, 2024 | SC 13G/A | |
12 Nov, 2024 | 10-Q | |
12 Nov, 2024 | 8-K | |
6 Sep, 2024 | EFFECT | |
4 Sep, 2024 | CORRESP | |
3 Sep, 2024 | UPLOAD | |
30 Aug, 2024 | S-3 | |
14 Aug, 2024 | 4 | |
12 Aug, 2024 | 10-Q | |
12 Aug, 2024 | 8-K | |
9 Aug, 2024 | 3 | |
2 Aug, 2024 | SC 13G | |
17 Jun, 2024 | 8-K | |
29 May, 2024 | DEFA14A | |
28 May, 2024 | 8-K | |
13 May, 2024 | 8-K | |
13 May, 2024 | 10-Q | |
29 Apr, 2024 | DEFA14A | |
29 Apr, 2024 | ARS | |
29 Apr, 2024 | DEF 14A | |
25 Apr, 2024 | 8-K | |
22 Mar, 2024 | SC 13D/A | |
21 Mar, 2024 | 8-K | |
21 Mar, 2024 | 10-K | |
11 Mar, 2024 | 4 | |
14 Feb, 2024 | 4 | |
14 Feb, 2024 | 4 | |
14 Feb, 2024 | 4 | |
14 Feb, 2024 | 4 | |
14 Feb, 2024 | 4 | |
9 Feb, 2024 | SC 13G/A | |
9 Feb, 2024 | 4 | |
9 Feb, 2024 | 4 | |
7 Feb, 2024 | SC 13G/A | |
1 Feb, 2024 | SC 13G | |
10 Jan, 2024 | 4 | |
10 Jan, 2024 | 4 | |
9 Jan, 2024 | 8-K | CEO Change |
5 Jan, 2024 | 8-K | |
27 Nov, 2023 | SC 13G | |
21 Nov, 2023 | 4 | |
21 Nov, 2023 | 4 | |
9 Nov, 2023 | 10-Q | |
9 Nov, 2023 | 8-K | |
3 Aug, 2023 | 8-K | |
3 Aug, 2023 | 10-Q | |
15 Jun, 2023 | 8-K | |
4 May, 2023 | 8-K | |
4 May, 2023 | 10-Q | |
27 Apr, 2023 | DEFA14A | |
27 Apr, 2023 | DEF 14A | |
27 Apr, 2023 | ARS | |
24 Apr, 2023 | 3 | |
24 Apr, 2023 | 4 | |
24 Apr, 2023 | 8-K | |
15 Mar, 2023 | 10-K | |
10 Mar, 2023 | 8-K | |
10 Mar, 2023 | 4 | |
27 Feb, 2023 | 4 | |
24 Feb, 2023 | 8-K | |
15 Feb, 2023 | 4 | |
14 Feb, 2023 | SC 13G/A | |
13 Feb, 2023 | SC 13G/A | |
10 Feb, 2023 | 4 | |
10 Feb, 2023 | 3 | |
10 Feb, 2023 | 8-K | |
9 Feb, 2023 | 4 | |
9 Feb, 2023 | 4 | |
9 Feb, 2023 | 4 | |
9 Feb, 2023 | 4 | |
9 Feb, 2023 | 4 | |
9 Feb, 2023 | SC 13G/A | |
9 Feb, 2023 | 4 | |
31 Jan, 2023 | 4 | |
24 Jan, 2023 | 424B3 | |
24 Jan, 2023 | 4 | |
20 Jan, 2023 | EFFECT | |
19 Jan, 2023 | 8-K | |
19 Jan, 2023 | CORRESP | |
17 Jan, 2023 | CORRESP | |
13 Jan, 2023 | CORRESP | |
7 Dec, 2022 | UPLOAD | |
2 Dec, 2022 | S-3 | |
29 Nov, 2022 | 8-K | |
22 Nov, 2022 | 4 | |
14 Nov, 2022 | SC 13D | |
10 Nov, 2022 | 3 | |
10 Nov, 2022 | SC 13D/A | |
10 Nov, 2022 | 4 | |
10 Nov, 2022 | 4 | |
9 Nov, 2022 | 10-Q | |
2 Nov, 2022 | 8-K | |
28 Sep, 2022 | 4 | |
27 Sep, 2022 | 4 | |
8 Sep, 2022 | 4 | |
1 Sep, 2022 | 4 | |
19 Aug, 2022 | 8-K | |
17 Aug, 2022 | 4 | |
10 Aug, 2022 | 4 | |
2 Aug, 2022 | 4 | |
1 Aug, 2022 | 10-Q | |
1 Aug, 2022 | 8-K | |
1 Aug, 2022 | 424B5 | |
21 Jun, 2022 | 4 | |
17 Jun, 2022 | 4 | |
13 Jun, 2022 | 4 | |
7 Jun, 2022 | 4 | |
1 Jun, 2022 | 4 | |
31 May, 2022 | 8-K | |
26 May, 2022 | 4 | |
24 May, 2022 | 4 | |
18 May, 2022 | DEFA14A | |
17 May, 2022 | 4 | |
13 May, 2022 | 4 | |
13 May, 2022 | 4 | |
10 May, 2022 | 4 | |
10 May, 2022 | 4 | |
10 May, 2022 | 4 | |
9 May, 2022 | 10-Q | |
4 May, 2022 | 8-K | |
28 Apr, 2022 | 4 | |
28 Apr, 2022 | 3 | |
28 Apr, 2022 | 4 | |
28 Apr, 2022 | DEF 14A | |
28 Apr, 2022 | 3 | |
26 Apr, 2022 | 8-K | |
18 Mar, 2022 | 10-K | |
25 Feb, 2022 | 8-K | |
23 Feb, 2022 | 4/A | |
23 Feb, 2022 | 4 | |
23 Feb, 2022 | 4 | |
23 Feb, 2022 | 4 | |
23 Feb, 2022 | 4 | |
23 Feb, 2022 | 4/A | |
23 Feb, 2022 | 4/A | |
18 Feb, 2022 | 4 | |
18 Feb, 2022 | 4 | |
18 Feb, 2022 | 4 | |
15 Feb, 2022 | SC 13G/A | |
9 Feb, 2022 | SC 13G/A | |
20 Jan, 2022 | 8-K | |
30 Dec, 2021 | SC 13G | |
21 Dec, 2021 | 8-K | |
17 Dec, 2021 | SC 13G/A | |
15 Dec, 2021 | 424B5 | |
15 Dec, 2021 | 424B5 | |
18 Nov, 2021 | 4 | |
18 Nov, 2021 | 4 | |
12 Nov, 2021 | SC 13G | |
12 Nov, 2021 | 10-Q | |
9 Nov, 2021 | SC 13D/A | |
8 Nov, 2021 | 4 | |
8 Nov, 2021 | 4 | |
3 Nov, 2021 | 8-K | |
3 Nov, 2021 | 424B5 | |
1 Nov, 2021 | CERT | |
1 Nov, 2021 | 8-K | |
1 Nov, 2021 | 424B5 | |
1 Nov, 2021 | 8-A12B | |
8 Oct, 2021 | 8-K | |
16 Aug, 2021 | 10-Q | |
5 Aug, 2021 | 8-K/A | |
20 Jul, 2021 | EFFECT | |
16 Jul, 2021 | CORRESP | |
15 Jul, 2021 | UPLOAD | |
14 Jul, 2021 | SC 13D/A | |
9 Jul, 2021 | S-3 | |
30 Jun, 2021 | 8-K | |
29 Jun, 2021 | 3 | |
29 Jun, 2021 | 4 | |
4 Jun, 2021 | 8-K | |
13 May, 2021 | 8-K | |
5 May, 2021 | 3 | |
5 May, 2021 | 4 | |
30 Apr, 2021 | 10-Q | |
30 Apr, 2021 | 424B3 | |
29 Apr, 2021 | DEF 14A | |
19 Apr, 2021 | 8-K | |
11 Mar, 2021 | 424B3 | |
8 Mar, 2021 | EFFECT | |
5 Mar, 2021 | POS AM | |
5 Mar, 2021 | 10-K | |
1 Mar, 2021 | 4 | |
1 Mar, 2021 | 4 | |
8 Feb, 2021 | SC 13G/A | |
14 Jan, 2021 | S-8 |
Last update:2025-03-06 12:09:25.558378
Sign Up to Subscribe
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.